Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Receives Orphan Drug Designation for Alport Syndrome Drug

Premium

NEW YORK (GenomeWeb) – Regulus Therapeutics this week announced that the US Food and Drug Administration has granted orphan drug status to the company's preclinical Alport syndrome therapy RG-012.

The condition is a rare kidney disease caused by mutations in three genes that affect production of the type IV collagen family of proteins. The result is a disruption to the structure of the glomerular basement membrane, increased expression of microR-21, an increase in fibrosis, and the loss of renal function, which ultimately leads to end-stage renal disease.

RG-012 is designed to silence miR-21. In mouse studies, inhibition of the miRNA has been shown to decrease the rates of decline of renal fibrosis while increasing the animals' life span.

Regulus is currently preparing to initiate a natural history of disease study to gather information on the progression of Alport syndrome and guide clinical development plans for RG-012.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.